• Explore /
  • Poster
  • / Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.

Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.

Abstract Poster

Authors

Fred Saad

Fred Saad

University of Montréal Health Center, Montréal, QC, Canada

Fred Saad , Maha H. A. Hussain , Bertrand F. Tombal , Karim Fizazi , Cora N. Sternberg , E. David Crawford , Silke Thiele , Rui Li , Iris Kuss , Heikki Joensuu , Matthew Raymond Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Hormone-Sensitive

Clinical Trial Registration Number

NCT02799602

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5078)

DOI

10.1200/JCO.2022.40.16_suppl.5078

Abstract #

5078

Poster Bd #

261

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Neal D. Shore

First Author: Mamta Parikh

First Author: Matthew Raymond Smith